Bentvelsen F M, Bogdanowicz J F, Oosterom R, Schröder F H
Afd. Urologie, Academisch Ziekenhuis Rotterdam-Dijkzigt.
Ned Tijdschr Geneeskd. 1990 Aug 18;134(33):1596-600.
A comparison is made of prostatic acid phosphatase (PAP) and prostate specific antigen (PSA) in the diagnosis of prostatic carcinoma. In a retrospective study PAP ans PSA were compared in 127 normal elderly men, in 187 patients with benign prostatic hyperplasia (BPH) and in 162 patients with untreated prostatic carcinoma. In the control group a normal value of 2.2 micrograms/l was found for PAP and 5.0 micrograms/l for PSA. In 41% of BPH patients the PSA level was higher than 5.0 micrograms/l. Because of this substantial percentage a cut-off value of 10 micrograms/l was used instead of 5.0 micrograms/l. In the BPH group 20% had a PSA level over 10 micrograms/l and 21% a PAP over 2.2 micrograms/l. Of the carcinoma patients without metastasis 57% had a PSA level over 10 micrograms/l and of those with metastatic disease, 92%. For PAP these percentages were 35 and 77, respectively. It is concluded that PSA is a more sensitive tumour marker than PAP.
对前列腺酸性磷酸酶（PAP）和前列腺特异性抗原（PSA）在前列腺癌诊断中的作用进行了比较。在一项回顾性研究中，对127名正常老年男性、187例良性前列腺增生（BPH）患者和162例未经治疗的前列腺癌患者的PAP和PSA进行了比较。在对照组中，PAP的正常值为2.2微克/升，PSA为5.0微克/升。在41%的BPH患者中，PSA水平高于5.0微克/升。由于这一比例较高，因此采用10微克/升而非5.0微克/升作为临界值。在BPH组中，20%的患者PSA水平超过10微克/升，21%的患者PAP超过2.2微克/升。在无转移的癌患者中，57%的患者PSA水平超过10微克/升，而有转移疾病的患者中这一比例为92%。对于PAP，这些百分比分别为35%和77%。结论是，PSA是比PAP更敏感的肿瘤标志物。
